Literature DB >> 18688050

Nationwide veterans affairs quality measure for cancer: the family assessment of treatment at end of life.

Esme Finlay1, Scott Shreve, David Casarett.   

Abstract

The Veterans Affairs (VA) health care system has created a national initiative to measure quality of care at the end of life. This article describes the first phase of this national initiative, the Family Assessment of Treatment at End of Life (FATE), in evaluating the quality of end-of-life care for veterans dying with cancer. In the initial phase, next of kin of patients from five VA Medical Centers were contacted 6 weeks after patients' deaths and invited to participate in a telephone interview, and surrogates for 262 cancer patients completed FATE interviews. Decedents were 98% male with an average age of 72 years. There was substantial variation among sites. Higher FATE scores, consistent with family reports of higher satisfaction with care, were associated with palliative care consultation and hospice referral and having a Do Not Resuscitate order at the time of death, whereas an intensive care unit death was associated with lower scores. Early experience with FATE suggests that it will be a helpful tool to characterize end-of-life cancer care and to identify targets for quality improvement.

Entities:  

Mesh:

Year:  2008        PMID: 18688050     DOI: 10.1200/JCO.2008.16.8534

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  18 in total

1.  Hospice admissions for cancer in the final days of life: independent predictors and implications for quality measures.

Authors:  Nina R O'Connor; Rong Hu; Pamela S Harris; Kevin Ache; David J Casarett
Journal:  J Clin Oncol       Date:  2014-08-25       Impact factor: 44.544

Review 2.  Hospital do-not-resuscitate orders: why they have failed and how to fix them.

Authors:  Jacqueline K Yuen; M Carrington Reid; Michael D Fetters
Journal:  J Gen Intern Med       Date:  2011-02-01       Impact factor: 5.128

3.  End-of-life care among head and neck cancer patients.

Authors:  Andrew G Shuman; Ye Yang; Jeremy M G Taylor; Mark E Prince
Journal:  Otolaryngol Head Neck Surg       Date:  2011-05       Impact factor: 3.497

4.  Timing of code status documentation and end-of-life outcomes in patients admitted to an oncology ward.

Authors:  Amanda Caissie; Nanor Kevork; Breffni Hannon; Lisa W Le; Camilla Zimmermann
Journal:  Support Care Cancer       Date:  2014-02       Impact factor: 3.603

5.  Investigation of Racial Disparities in Early Supportive Medication Use and End-of-Life Care Among Medicare Beneficiaries With Stage IV Breast Cancer.

Authors:  Devon K Check; Cleo A Samuel; Donald L Rosenstein; Stacie B Dusetzina
Journal:  J Clin Oncol       Date:  2016-05-09       Impact factor: 44.544

6.  It is possible: quality measurement during serious illness.

Authors:  Melissa D Aldridge; Diane E Meier
Journal:  JAMA Intern Med       Date:  2013 Dec 9-23       Impact factor: 21.873

7.  Does Quality of End-of-Life Care Differ by Urban-Rural Location? A Comparison of Processes and Family Evaluations of Care in the VA.

Authors:  Cindy Del Rosario; Ann Kutney-Lee; Julie Sochalski; Mary Ersek
Journal:  J Rural Health       Date:  2019-02-11       Impact factor: 4.333

Review 8.  Measuring Experience With End-of-Life Care: A Systematic Literature Review.

Authors:  Jessica Penn Lendon; Sangeeta C Ahluwalia; Anne M Walling; Karl A Lorenz; Oluwatobi A Oluwatola; Rebecca Anhang Price; Denise Quigley; Joan M Teno
Journal:  J Pain Symptom Manage       Date:  2014-12-24       Impact factor: 3.612

9.  Organization of nursing and quality of care for veterans at the end of life.

Authors:  Ann Kutney-Lee; Caitlin W Brennan; Mark Meterko; Mary Ersek
Journal:  J Pain Symptom Manage       Date:  2014-08-10       Impact factor: 3.612

10.  Quality of End-of-Life Care Provided to Patients With Different Serious Illnesses.

Authors:  Melissa W Wachterman; Corey Pilver; Dawn Smith; Mary Ersek; Stuart R Lipsitz; Nancy L Keating
Journal:  JAMA Intern Med       Date:  2016-08-01       Impact factor: 21.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.